Background: We analysed trends in incidence for in situ and invasive melanoma in some European countries during the period 1995e2012, stratifying for lesion thickness. Material and methods: Individual anonymised data from population-based European cancer registries (CRs) were collected and combined in a common database, including information on age, sex, year of diagnosis, histological type, tumour location, behaviour (invasive, in situ) and lesion thickness. Mortality data were retrieved from the publicly available World Health Organization database. Results: Our database covered a population of over 117 million inhabitants and included about 415,000 skin lesions, recorded by 18 European CRs (7 of them with national coverage). During the 1995e2012 period, we observed a statistically significant increase in incidence for both invasive (average annual percent change (AAPC) 4.0% men; 3.0% women) and in situ (AAPC 7.7% men; 6.2% women) cases. Discussion: The increase in invasive lesions seemed mainly driven by thin melanomas (AAPC 10% men; 8.3% women). The incidence of thick melanomas also increased, although more slowly in recent years. Correction for lesions of unknown thickness enhanced the differences between thin and thick cases and flattened the trends. Incidence trends varied considerably across registries, but only Netherlands presented a marked increase above the boundaries of a funnel plot that weighted estimates by their precision. Mortality from invasive melanoma has continued to increase in Norway, Iceland (but only for elder people), the Netherlands and Slovenia. ª
Introduction
The incidence of cutaneous malignant melanoma has increased steeply since the Second World War [1e7] although recent observations show a stabilisation of rates in North America and Australia [2] . In these countries, prevention campaigns and interventions aimed at early diagnosis have been implemented, with the aims of limiting solar exposure (especially at younger ages) and of detecting suspicious lesions as early as possible. However, a clear decrease in melanoma mortality in all age groups [8e11] has not yet been observed.
Some countries have recently noted evidence of decrease in the incidence of invasive melanoma. However the reasons for the decline are not clear from the data and may be due to sun prevention campaigns or earlier diagnosis or both. An important element in understanding the trends is the concurrent behaviour of in situ, thin and thick lesions. Some studies have shown that the incidence of in situ and thin melanomas has been increasing faster than that of thick melanomas [9,12e19] .
At present, information on the incidence of in situ, thin and thick lesions is collected by many cancer registries in Europe, but statistics on thickness are not available on a routine basis from most of the public access sites. In addition, published studies often focus on the national burden of the disease, lacking a broader European perspective.
This article investigated melanoma incidence and mortality in 13 European countries during the period 1995e2012. To better understand trends, analyses were performed by country, age, sex and Breslow thickness.
Materials and methods
Individual anonymised incidence data (with corresponding population files) were collected from population-based European cancer registries (CRs) through an ad hoc call. CRs directors and researchers received the study protocol by e-mail by the end of year 2015. CRs were selected on the basis of a long history of highquality data (as proven by inclusion in the last two editions of Cancer Incidence in Five Continents, low percentages of DCO and high proportions of MV for melanoma); at least ten years of complete registration; a sufficiently large population to avoid large year-to-year variation; and availability of information on thickness. Registries in Cluj, Geneva, Iceland, and Ragusa were also included to ensure representation of a wide range of geographical areas.
To minimise the workload of CRs, data were accepted in any format available and for any period which CRs could provide. This helped ensure a broader perspective and reflected the heterogeneity of European cancer registration activity. However, after data cleaning and the pre-processing of all CRs data files, the analysis focused on cases diagnosed between 1995 and 2012.
A common anonymised database was created containing the following variables for each case: age at diagnosis, sex, year of diagnosis, histological type, tumour location, behaviour (invasive, in situ), Breslow thickness, vital status (dead or alive) and cause of death if melanoma. In the analyses, histological types were categorised as 'superficial spreading melanoma' (SSM), 'nodular melanoma' (NM), 'lentigo maligna melanoma' (LM) and 'other'; whereas cancer body sites were grouped as 'head and neck', 'limbs', 'trunk' and 'other'.
Mortality data were retrieved from the World Health Organization (WHO) mortality database [20] to allow a broader comparison among countries.
Annual incidence and mortality rates were age e standardised on the World population (following the Segi standard).
In situ incidence trends were analysed taking care of specific problems highlighted by registries (Cluj CR did not collect this type of lesions and was excluded; Norway CR was included only for the period 1995e2008, because since 2009 it registered only in situ cases that later become malignant).
Invasive lesions were grouped by thickness, as: 'thin' for those 1.00 mm (as defined by TNM since the 6th Edition) and otherwise as 'thick'. Cases without Breslow thickness information were analysed separately as 'unknown'. Moreover, to minimise bias [21] , where a high proportion of cases had missing thickness, incidence trends by Breslow level were also analysed after the imputation of thickness information on the basis that it was missing at random. The number of unknown cases n unk was taken as being made up of n u thin þ n u thick (the number of thin and thick lesions). The ratio n u thin n u thick was taken to be equal to the known proportion of thin and thick lesions for the same period, sex and age group (Appendix A for details). Thin/thick ratios were calculated for each age, sex, and period stratum, so the correction was specific to each combination of stratification variables. In this way, a corrected number of thin and thick cases was obtained by adding the calculated components to the original ones, by sex, period, and age group. The correction was done for all cases combined and also on a registry-by-registry basis: the results were similar (with some more instability due to small numbers, when stratified by registry), and we report here only trends corrected for all cases combined.
We used Joinpoint regression models 1 (assuming log transformation of data, homoscedasticity in error variance, and setting other parameters as default) to determine incidence trends and the timing of any changes. From these analyses, we report the annual percent change (APC) and the average annual percent change (AAPC). Funnel plots have been included to show the precision of single-registry estimates.
All analyses were performed using SAS/STAT Version 9.2, R Version 3.3.2 and Joinpoint Version 4.2.02.
Results
Our database covered a population of over 117 million inhabitants and included about 415,000 skin lesions, recorded by 18 European CRs (7 of them with national coverage) in 13 countries, between 1995 and 2012 (Table  1 ). Incidence rates of invasive melanoma in men varied from a low of 5.6 per 100,000 in Tarragona, Spain to 24/ 100,000 in Geneva, Switzerland, where the highest rate of in situ lesions was also observed, 23/100,000 in men in 2012 ( Table 1 ). Incidence rates were higher among females in nearly all cancer registries. The median age at diagnosis was 61 years in men and 56 in women. In situ lesions made up about one-quarter of all cases. SSM was the commonest invasive histological subtype (46%) and about 50% of invasive lesions were located on the limbs. However, the body site distribution of lesions was quite different between men and women, with 43% of melanoma on the trunk in men and 57% on the limbs in women. Overall, time trends showed similar patterns for both sexes and are reported together in Figs. 2 and 3. After the exclusion of Austria, Scotland for the period 1995e2005 and Norway for the period 1995e2008, due to the lack of thickness information for all cases recorded, thin and thick melanomas were present in our database in similar proportions (38% and 34% respectively); 28% of cases had missing information on thickness, with the highest proportion of missing information in earlier years.
Incidence trends
The combined data for all participating CRs showed a statistically significant incidence increase in both invasive (AAPC 4.0%, 95% confidence interval [CI]: 3.8 À 4.2 in men; AAPC 3.0%, 95% CI: 2.3À3.8 in women) and in situ (AAPC 7.7%, 95% CI: 7.3 À 8.1 in men; AAPC 6.2%, CI: 5.9 À 6.6 in women) lesions for both men and women, during the 1995e2012 period ( Table 2 and Fig. 1 ).
The trend in invasive cases seemed mainly due to the increasing incidence of thin lesions, with an average annual increase of 8.3% (95% CI: 7.6 À 9.1) in women and an even greater increase (10%, 95% CI: 9.6 e 11.3) in men. The incidence of thick melanomas also increased; however in recent years the rate of increase was less than for thin melanomas, with a reduction in APC from 12% to 4.3% in women and from 10% to 6.0% in men. A large part of the increase in incidence was for lesions on the limbs and trunk; lesions of head and neck also increased in incidence, although less rapidly ( Fig. 2) . SSM, the most prevalent histological sub-type, showed the largest increase, whereas NM and LM increased more gradually (Fig. 3 ).
The steepest increase in incidence occurred in the period 1998 and 2001, in particular in thick melanomas in women. This finding was confirmed after correction for the number of melanomas with unknown thickness (APC 0.6% before 1998, 5.4% between 1998 and 2001, and 1.7% after 2001). The increase in thin melanomas lasted until 2001 (APC 11%) and slowed after that year (APC 8.2%, Table 2 ). However, these changes in trend emerged for thin melanomas only before the correction for those of unknown thickness. After the imputation of missing information, thin melanoma increased at a steady (and lower) rate for the entire period ( Table 3 ).
The completeness of information collected by CRs increased overtime, most clearly after 2005/2007 (cases with unknown thickness decreased to À5.7% after 2005 in men and to À8.1% after 2007 in women, Table 2 ).
Correction for lesions of unknown thickness (methods described in Appendix A), enhanced the differences between thin and thick lesions and flattened their trends: in particular, for thin melanoma, the APC Table 1 National (N) and regional (R) cancer registries which contributed to the project. in men was roughly halved (from 13% to 6.3%), whereas in women, the average annual increase was reduced to 4.6% (Table 3 and Fig. 4 ). Incidence trends varied considerably among registries ( Table 4 ). The AAPC for invasive lesions in women varied from À0.5% (SchleswigeHolstein, Germany) to 14% (Cluj, Romania). Incidence trends for in situ lesions in men varied from a decrease in AAPC of À2.9% (Ragusa, Italy) to an increase of 24% (Geneva, Switzerland). However, when we compared estimates of AAPC with their precision in a funnel plot, we noted that the observed differences across registries were mainly due to random variation (Fig. 5 ). Only the AAPC in men in Netherlands was outside the 3s upper boundary of the funnel plot for invasive lesions (Fig. 5, Panel A) .
Mortality trends
Melanoma world age e standardised mortality rates ranged from 1 to 4 cases per 100,000 and the increase in mortality, where present, was much smaller than that in incidence. Rates continue to increase in Northern Europe, in particular in Iceland (AAPC 5.4%), Ireland (AAPC 3.4%), and Norway (AAPC 1.6%). In Western Europe, the Netherlands (AAPC 2.1%) and Belgium (AAPC 1.0%) showed a statistically significant increasing trend; in Southern and Eastern Europe only Slovenia (AAPC 2.0%) presented a significant increase in melanoma mortality ( Table 5 and Fig. 6 ). Men exhibited higher rates than women, as survival is poorer among men [22, 23] , but, in general, trends were parallel, with the exception of Ireland, UK, Germany and Slovenia, where men showed higher increases than women, in particular in the last period (Table 5 ). Europe have been  previously  analysed  at  a  national  level  [3,8e10,14e19,24e34] . However, the different periods considered and methods used have hampered comparisons between countries. Moreover, differences in incidence and mortality trends in both time and space have made it difficult to interpret mortality-incidence ratios, which are often used as a proxy for survival, and are also used to estimate incidence in areas not covered by registration [35] .
Discussion

Melanoma incidence trends in
In this study, we provide a broad overview of the continent, using data collected by CRs. We restricted our analysis to a short period (1995e2012) to accommodate the largest number of registries (but there are CRs with data available for a much longer period) and to avoid an overestimation of increase in trends (especially for the in situ lesions), simply due to the improvement in the completeness of melanoma cases registered.
A major limitation of this study was that several CRs have registered in situ melanomas only in recent years and have limited information on the thickness of lesions. Even CRs with a long history of data collection lacked information on Breslow thickness for a large proportion of cases, especially in earlier years. Missing information on thickness, particularly where the proportion missing varied during the period analysed, could have led to significant bias. The same considerations applied to in situ lesions, which were collected and recorded by CRs with greater accuracy and completeness in more recent years. However, the lack of changes in the slope of the increasing incidence trend of in situ cases and the attention paid to problems highlighted by different CRs (which led to the exclusion of Cluj CR and (partly) of Norway CR for this analysis) made us confident of the reality of the observed increase.
With respect to invasive cases, we reduced bias by reclassifying lesions of unknown thickness as either thin or thick, according to the observed ratio of thin and thick lesions by sex, age and period. Although this method may help to adjust estimates toward the true rate, some bias is unavoidable as the true thin/thick ratio has not been completely observed, and it is difficult to know if the estimates have been biased upward or downward. Moreover, we could not exclude that the correction induced a small bias because of the assumption of randomness in missing information: actually, the distribution of unknown cases with respect to histology, body site and follow-up (data not shown) seemed more similar to that of thick lesions.
Within these limitations, there is a clear picture of a continuing upward trend in both invasive and in situ melanoma in Europe. We observed that, in recent years, the burden of in situ lesions has increased in parallel Table 2 Annual Percent Change (APC) highlighted by the Joinpoint models in melanoma incidence trends in Europe in the period 1995e2012. Analysis performed before imputing the missing information on Breslow level. Table 3 Annual Percent Change (APC) highlighted by the Joinpoint models in melanoma incidence trends in Europe in the period 1995e2012. Analyses performed after the correction for cases with unknown thickness. with that of thick lesions. Taking in situ and thin melanoma together, there is an annual burden of 20 new cases per 100,000 inhabitants in Europe, with considerable impact on patients and health-care services. The increase in incidence was particularly evident in Norway and Iceland, although the difference between trends in invasive lesions and that of in situ melanoma was less striking than in other countries such as Austria, Slovenia, Switzerland (Geneva), Spain (Tarragona) and Italy (Turin).
In the period 1995e2012, melanoma mortality increased slightly in Norway, Iceland, Ireland, Netherlands, Belgium and Slovenia and overall approached the AAPC increase in incidence of thick lesions. In the most recent years, a steeper increase has been observed among men in Ireland, UK, Germany and Slovenia. However some evidence of decline in mortality has been reported in younger cohorts in some countries [36, 37] , and Autier et al. [38] proposed a scenario of declining trends in the recent future, due to the ageing of younger cohorts supposedly less exposed to UV during childhood. Even if the hypothesis of a decreased UV exposure in younger cohorts will be confirmed, our findings, with an increasing trend of thick lesions in incidence for all ages, are pointing towards a less optimistic scenario for melanoma mortality in the next years.
Previous publications from European countries have shown increasing trends in the incidence of invasive lesions, mainly due to increases in thinner melanomas, as well as a small continuing increase in mortality (with some evidence of stabilisation in Switzerland [9, 28] and decreases in mortality in women in Denmark [17] and Northern Ireland [19] which are not statistically significant). Lower incidence and higher mortality rates have been reported in South-Eastern European countries compared with North-Western countries [29] . The Fig. 4 . Cutaneous malignant melanoma incidence, after correction for unknown. Europe, 1995e2012. Both sexes. World age standardised incidence trends for melanoma lesions in Europe in the period 1995e2012, after correction for cases with unknown Breslow level. Dots represent the observed values; dashed lines the Joinpoint models. Table 4 Average Annual Percent Change (AAPC) for incidence of invasive and in situ lesions by single registry, in the period 1995e2012. incidence of in situ cases has increased dramatically [14, 15, 17, 26, 30] , often at a greater rate than more aggressive lesions.
AAPC
Outside Europe, melanoma trends have been investigated in United States and Australia [4, 5, 12, 13, 39, 40] . Coory et al. [12] reported a steep increase in the incidence of in situ and thin melanomas in the period 1982e2002, whereas Baade et al. [13] , looking at more recent years, reported that trends in thinner lesions have now reached a plateau in Australia. On the other hand, mortality trends seem to have been stable for many years, although a non-negligible fraction of thin cases appears to result in death [41] . In the United States, SEER data showed increasing trends for invasive (APC Z þ3.6%) and in situ lesions (APC Z þ9.5%) [39] , whereas mortality scarcely increased (by 0.4% between 1992 and 2004). Analysing SEER data [42] we noticed a stabilisation in the incidence of invasive cases in the last years, whereas in the European database there was a continuing increase, although with rates only half of those in the United States. Continuing increases in the incidence of in situ lesions are seen in both SEER and Europe trends. Data from the Connecticut Tumor Registry have shown an increase in the proportion of thinner lesions in the most recent period [5] . Although SEER data on Breslow thickness are not completely reliable, due to inconsistencies in the coding of thickness [43] , Shaikh et al. [40] applied a validated imputation method for missing Breslow information (on about the 13% of cases) and showed that the incidence increased across all thickness groups in the period 1989e2009, most pronounced for thinner lesions. In conclusion, this study has shown that the incidence of invasive cutaneous malignant melanoma increased sharply in Europe during the period 1995e2012 in both sexes; this rise was mainly attributable to thinner lesions. In situ lesions have also increased in incidence, with a steeper trend than that for invasive cases; however, the incidence of thick lesions has also increased to a lesser extent.
Seemingly, earlier diagnosis could not counterbalance a generalised increase in melanoma risk as we still observe an increase in thick lesions and also a slight increase of melanoma mortality in six of the 13 European countries included in this study.
For these reasons, we can conclude that in Europe we cannot dismiss the need for further efforts in preventive actions for limiting exposure to environmental hazards, especially in childhood as suggest by the European Code Against Cancer [44] , as a way for avoiding thick lesions occurrence. Furthermore, advances in research for better targeting earlier detection of aggressive melanoma lesions are much needed.
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Appendix A. Correction for cases with unknown thickness
Under the assumption that the thickness information was missed at random, the estimated number of thin and thick cases was obtained solving the following system of equation: where Thin F ijk and Thick F ijk represented the corrected number of thin and thick cases respectively.
